Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
Sponsor: M.D. Anderson Cancer Center
Summary
The goal of this clinical research study is to learn if adding cidofovir to the standard of care can improve symptoms of hemorrhagic cystitis caused by the BK virus as compared to standard of care alone. The safety of cidofovir will also be studied.
Official title: A Phase II Randomized Study of Cidofovir Versus Best Supportive Care for Polyomavirus Hominis Type I (BK) Virus Related Hemorrhagic Cystitis After Stem Cell Transplant
Key Details
Gender
All
Age Range
6 Years - Any
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2011-03-17
Completion Date
2028-03-15
Last Updated
2026-03-06
Healthy Volunteers
No
Conditions
Interventions
Cidofovir
0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
No Cidofovir
Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
Locations (1)
University of Texas MD Anderson Cancer Center
Houston, Texas, United States